JP2020532967A5 - - Google Patents

Download PDF

Info

Publication number
JP2020532967A5
JP2020532967A5 JP2020511253A JP2020511253A JP2020532967A5 JP 2020532967 A5 JP2020532967 A5 JP 2020532967A5 JP 2020511253 A JP2020511253 A JP 2020511253A JP 2020511253 A JP2020511253 A JP 2020511253A JP 2020532967 A5 JP2020532967 A5 JP 2020532967A5
Authority
JP
Japan
Prior art keywords
optionally
protein
domain
mutations
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020511253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532967A (ja
JP7581046B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/047577 external-priority patent/WO2019040650A1/en
Publication of JP2020532967A publication Critical patent/JP2020532967A/ja
Publication of JP2020532967A5 publication Critical patent/JP2020532967A5/ja
Priority to JP2024080681A priority Critical patent/JP2024112895A/ja
Application granted granted Critical
Publication of JP7581046B2 publication Critical patent/JP7581046B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020511253A 2017-08-23 2018-08-22 変更されたPAM特異性を有する遺伝子操作されたCRISPR-Cas9ヌクレアーゼ Active JP7581046B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024080681A JP2024112895A (ja) 2017-08-23 2024-05-17 変更されたPAM特異性を有する遺伝子操作されたCRISPR-Cas9ヌクレアーゼ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762549303P 2017-08-23 2017-08-23
US62/549,303 2017-08-23
US201862641687P 2018-03-12 2018-03-12
US62/641,687 2018-03-12
PCT/US2018/047577 WO2019040650A1 (en) 2017-08-23 2018-08-22 GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024080681A Division JP2024112895A (ja) 2017-08-23 2024-05-17 変更されたPAM特異性を有する遺伝子操作されたCRISPR-Cas9ヌクレアーゼ

Publications (3)

Publication Number Publication Date
JP2020532967A JP2020532967A (ja) 2020-11-19
JP2020532967A5 true JP2020532967A5 (enExample) 2021-09-30
JP7581046B2 JP7581046B2 (ja) 2024-11-12

Family

ID=65439890

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511253A Active JP7581046B2 (ja) 2017-08-23 2018-08-22 変更されたPAM特異性を有する遺伝子操作されたCRISPR-Cas9ヌクレアーゼ
JP2024080681A Pending JP2024112895A (ja) 2017-08-23 2024-05-17 変更されたPAM特異性を有する遺伝子操作されたCRISPR-Cas9ヌクレアーゼ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024080681A Pending JP2024112895A (ja) 2017-08-23 2024-05-17 変更されたPAM特異性を有する遺伝子操作されたCRISPR-Cas9ヌクレアーゼ

Country Status (8)

Country Link
US (3) US11286468B2 (enExample)
EP (1) EP3672612A4 (enExample)
JP (2) JP7581046B2 (enExample)
CN (2) CN111278450B (enExample)
AU (3) AU2018320865B2 (enExample)
BR (1) BR112020003596A2 (enExample)
CA (1) CA3073448A1 (enExample)
WO (1) WO2019040650A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
EP3919621A1 (en) 2014-06-23 2021-12-08 The General Hospital Corporation Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
JP6817215B2 (ja) 2015-03-03 2021-01-20 ザ ジェネラル ホスピタル コーポレイション 変更PAM特異性を有する遺伝子操作CRISPR−Cas9ヌクレアーゼ
CN108350453A (zh) 2015-09-11 2018-07-31 通用医疗公司 核酸酶dsb的完全查询和测序(find-seq)
US11168313B2 (en) 2016-07-26 2021-11-09 The General Hospital Corporation Variants of CRISPR from Prevotella and Francisella 1 (Cpf1)
WO2018119010A1 (en) 2016-12-19 2018-06-28 Editas Medicine, Inc. Assessing nuclease cleavage
EP3565907B1 (en) 2017-01-06 2022-05-04 Editas Medicine, Inc. Methods of assessing nuclease cleavage
ES2992912T3 (en) 2017-04-21 2024-12-19 Massachusetts Gen Hospital Variants of cpf1 (cas12a) with altered pam specificity
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
AU2018273986A1 (en) 2017-05-25 2019-12-12 The General Hospital Corporation Bipartite base editor (BBE) architectures and type-II-C-Cas9 zinc finger editing
JP7518620B2 (ja) 2017-06-09 2024-07-18 エディタス・メディシン,インコーポレイテッド 操作されたcas9ヌクレアーゼ
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
CA3073448A1 (en) 2017-08-23 2019-02-28 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
EP3781585A4 (en) 2018-04-17 2022-01-26 The General Hospital Corporation SENSITIVE IN VITRO TESTS FOR SUBSTRATE PREFERENCES AND SITE FOR NUCLEIC ACID BINDERS, MODIFIERS AND CLEAVAGE AGENTS
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
KR20250133482A (ko) * 2018-05-11 2025-09-05 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일 뉴클레오티드 다형성을 편집하는 방법
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
AU2019336245B2 (en) 2018-09-07 2026-02-26 Beam Therapeutics Inc. Compositions and methods for delivering a nucleobase editing system
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
CN114040977B (zh) 2019-01-31 2024-09-03 比姆医疗股份有限公司 非靶脱氨反应减低的核碱基编辑器和用于定性核碱基编辑器的测定
EP3921417A4 (en) 2019-02-04 2022-11-09 The General Hospital Corporation VARIANTS OF ADENINE DNA BASES WITH REDUCED OFF-TARGET RNA EDIT
AU2020223314A1 (en) 2019-02-13 2021-08-12 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
SG11202108346WA (en) 2019-02-13 2021-08-30 Beam Therapeutics Inc Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
CN112266418A (zh) * 2019-07-08 2021-01-26 中国科学院微生物研究所 改进的基因组编辑系统及其应用
CN112280771A (zh) * 2019-07-10 2021-01-29 中国科学院遗传与发育生物学研究所 双功能基因组编辑系统及其用途
EP4021945A4 (en) * 2019-08-30 2023-11-15 The General Hospital Corporation Combinatorial adenine and cytosine dna base editors
AU2020345830A1 (en) * 2019-09-09 2022-03-24 Beam Therapeutics Inc. Novel CRISPR enzymes, methods, systems and uses thereof
CN115279398B (zh) 2019-09-27 2025-07-04 比姆医疗股份有限公司 治疗液态癌症的组合物和方法
US12497609B2 (en) 2019-10-14 2025-12-16 Yonsei University Biohealth Technology Holdings. Inc. Protospacer adjacent motif sequence and method for modifying target nucleic acid in genome of cell by using same
WO2021151085A2 (en) 2020-01-24 2021-07-29 The General Hospital Corporation Crispr-cas enzymes with enhanced on-target activity
WO2021151073A2 (en) * 2020-01-24 2021-07-29 The General Hospital Corporation Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants
EP4114937A4 (en) 2020-03-04 2024-09-04 Flagship Pioneering Innovations VI, LLC METHODS AND COMPOSITIONS FOR MODULATING A GENOME
US12576151B2 (en) 2020-09-25 2026-03-17 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
CN112430613A (zh) * 2020-12-08 2021-03-02 安徽省农业科学院水稻研究所 一种宽编辑范围的SpG基因及其应用
WO2022152746A1 (en) 2021-01-13 2022-07-21 Alia Therapeutics Srl K526d cas9 variants and applications thereof
KR20260037664A (ko) 2021-09-08 2026-03-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 게놈을 조절하기 위한 방법 및 조성물
WO2023039435A2 (en) 2021-09-08 2023-03-16 Flagship Pioneering Innovations Vi, Llc Pah-modulating compositions and methods
CN116286736B (zh) * 2022-01-17 2026-05-01 四川大学 一种具有扩大的pam识别范围的融合蛋白及其应用
WO2025087413A1 (zh) * 2023-10-25 2025-05-01 上海津曼特生物科技有限公司 靶向ttr的基因编辑组合物
WO2025158391A2 (en) * 2024-01-24 2025-07-31 The General Hospital Corporation Generation of custom crispr-cas9 pam variant enzymes
CN118048343B (zh) * 2024-03-01 2025-01-28 上海交通大学 Cas9核酸酶及其制备方法和用途
CN120005854B (zh) * 2025-04-18 2025-08-05 广州瑞风生物科技有限公司 Cas9突变体、基因编辑系统及应用
CN120665840A (zh) * 2025-05-30 2025-09-19 浙江大学 Cas9蛋白突变体及其应用

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090607A1 (en) 2004-03-08 2005-09-29 Rubicon Genomics, Inc. Methods and compositions for generating and amplifying dna libraries for sensitive detection and analysis of dna methylation
CA2615323A1 (en) 2005-06-06 2007-12-21 454 Life Sciences Corporation Paired end sequencing
ATE510930T1 (de) 2005-08-02 2011-06-15 Rubicon Genomics Inc Zusammensetzungen und verfahren zur bearbeitung und amplifikation von dna mit verwendung mehrerer enzyme in einer einzigen reaktion
NZ597299A (en) 2005-08-26 2013-03-28 Dupont Nutrition Biosci Aps Use of a cas gene in combination with CRISPR repeats for modulating resistance in a cell
WO2007059041A2 (en) 2005-11-11 2007-05-24 Pfizer, Inc. Combinations and methods of using an immunomodulatory oligodeoxynucleotide
PT2126130E (pt) 2007-03-02 2015-08-03 Dupont Nutrition Biosci Aps Culturas com resistência melhorada a fagos
WO2009027978A1 (en) 2007-08-30 2009-03-05 Hadasit Medical Research Services & Development Ltd. NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
US8029993B2 (en) 2008-04-30 2011-10-04 Population Genetics Technologies Ltd. Asymmetric adapter library construction
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
US8383345B2 (en) 2008-09-12 2013-02-26 University Of Washington Sequence tag directed subassembly of short sequencing reads into long sequencing reads
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US9404098B2 (en) 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
EP2367938B1 (en) 2008-12-12 2014-06-11 DuPont Nutrition Biosciences ApS Genetic cluster of strains of streptococcus thermophilus having unique rheological properties for dairy fermentation
JP5387839B2 (ja) 2009-09-04 2014-01-15 アイシン・エィ・ダブリュ株式会社 ナビゲーション装置、ナビゲーション方法、及びナビゲーションプログラム
US9023769B2 (en) 2009-11-30 2015-05-05 Complete Genomics, Inc. cDNA library for nucleic acid sequencing
US9493827B2 (en) 2010-01-14 2016-11-15 Deutsches Krebsforschungszentrum Determination of in vivo DNA double-strand break localization and application thereof
JP2013518602A (ja) 2010-02-09 2013-05-23 サンガモ バイオサイエンシーズ, インコーポレイテッド 部分的に一本鎖のドナー分子による標的化ゲノム改変
US10087431B2 (en) 2010-03-10 2018-10-02 The Regents Of The University Of California Methods of generating nucleic acid fragments
EA024121B9 (ru) 2010-05-10 2017-01-30 Дзе Реджентс Ов Дзе Юниверсити Ов Калифорния Композиции эндорибонуклеаз и способы их использования
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
WO2013078470A2 (en) 2011-11-22 2013-05-30 MOTIF, Active Multiplex isolation of protein-associated nucleic acids
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
EP2847353B1 (en) 2012-05-10 2022-01-19 The General Hospital Corporation Methods for determining a nucleotide sequence
LT3401400T (lt) 2012-05-25 2019-06-10 The Regents Of The University Of California Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
JP6181751B2 (ja) 2012-06-18 2017-08-16 ニューゲン テクノロジーズ, インコーポレイテッド 望まれない核酸配列のネガティブ選択のための組成物および方法
US20140024542A1 (en) 2012-07-17 2014-01-23 Counsyl, Inc. Methods and compositions for enrichment of target polynucleotides
AU2012385961B9 (en) 2012-07-24 2017-05-18 Natera, Inc. Highly multiplex PCR methods and compositions
WO2014071070A1 (en) 2012-11-01 2014-05-08 Pacific Biosciences Of California, Inc. Compositions and methods for selection of nucleic acids
CN104903466B (zh) 2012-11-05 2016-11-23 鲁比康基因组学公司 条形编码核酸
EP2931898B1 (en) 2012-12-12 2016-03-09 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
EP2896697B1 (en) 2012-12-12 2015-09-02 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
JP2016504026A (ja) 2012-12-12 2016-02-12 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための系、方法および最適化ガイド組成物のエンジニアリング
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
IL239317B (en) 2012-12-12 2022-07-01 Broad Inst Inc Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
ES2576126T3 (es) 2012-12-12 2016-07-05 The Broad Institute, Inc. Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias
CN114634950A (zh) 2012-12-12 2022-06-17 布罗德研究所有限公司 用于序列操纵的crispr-cas组分系统、方法以及组合物
AU2013359146B2 (en) 2012-12-13 2017-12-07 Corteva Agriscience Llc DNA detection methods for site specific nuclease activity
CA2897932A1 (en) 2013-01-14 2014-07-17 Recombinetics, Inc. Hornless livestock
US20140212869A1 (en) 2013-01-25 2014-07-31 Agilent Technologies, Inc. Nucleic Acid Proximity Assay Involving the Formation of a Three-way junction
CA2900338C (en) 2013-02-07 2024-11-05 The General Hospital Corporation TRANSCRIPTIONAL ACTIVATORS TALE
EP2958996B1 (en) 2013-02-25 2019-10-16 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
SG11201507378UA (en) 2013-03-14 2015-10-29 Caribou Biosciences Inc Compositions and methods of nucleic acid-targeting nucleic acids
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
US10378027B2 (en) 2013-03-15 2019-08-13 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
RU2723130C2 (ru) 2013-04-05 2020-06-08 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Способы и композиции для встраивания экзогенной последовательности в геном растений
DK2986729T3 (en) 2013-04-16 2018-10-29 Regeneron Pharma TARGETED MODIFICATION OF ROOT THROUGH
CA2910427C (en) 2013-05-10 2024-02-20 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
EP3004339B1 (en) 2013-05-29 2021-07-07 Cellectis New compact scaffold of cas9 in the type ii crispr system
WO2014204724A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
JP6665088B2 (ja) 2013-06-17 2020-03-13 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための最適化されたCRISPR−Cas二重ニッカーゼ系、方法および組成物
JP6482546B2 (ja) 2013-07-19 2019-03-13 ラリクス・バイオサイエンス・リミテッド・ライアビリティ・カンパニーLarix Bioscience, Llc 二重対立遺伝子ノックアウトを生成するための方法および組成物
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
WO2015074017A1 (en) 2013-11-18 2015-05-21 Rubicon Genomics Degradable adaptors for background reduction
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
WO2015089473A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
DK3604544T3 (en) 2014-01-31 2022-02-14 Swift Biosciences Inc Improved methods for processing dna substrates
EP3919621A1 (en) 2014-06-23 2021-12-08 The General Hospital Corporation Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)
AU2016206870B2 (en) 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
MA41349A (fr) 2015-01-14 2017-11-21 Univ Temple Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn
JP6817215B2 (ja) * 2015-03-03 2021-01-20 ザ ジェネラル ホスピタル コーポレイション 変更PAM特異性を有する遺伝子操作CRISPR−Cas9ヌクレアーゼ
IL293323B2 (en) 2015-06-18 2024-01-01 Massachusetts Inst Technology Crispr enzyme mutations reducing off-target effects
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2017015015A1 (en) 2015-07-17 2017-01-26 Emory University Crispr-associated protein from francisella and uses related thereto
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
AU2016316845B2 (en) 2015-08-28 2022-03-10 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
CN108350453A (zh) 2015-09-11 2018-07-31 通用医疗公司 核酸酶dsb的完全查询和测序(find-seq)
JP2018529353A (ja) 2015-09-30 2018-10-11 ザ ジェネラル ホスピタル コーポレイション 配列決定法による切断事象の包括的生体外報告(CIRCLE−seq)
SG10202104041PA (en) * 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
EP3845668A1 (en) 2015-10-30 2021-07-07 New England Biolabs, Inc. Compositions and methods for determining modified cytosines by sequencing
AU2016348439B2 (en) 2015-11-04 2023-03-09 Atreca, Inc. Combinatorial sets of nucleic acid barcodes for analysis of nucleic acids associated with single cells
EP3374501B1 (en) 2015-11-11 2023-07-12 Lonza Ltd Crispr-associated (cas) proteins with reduced immunogenicity
US9896696B2 (en) 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
CN105543195A (zh) * 2016-03-01 2016-05-04 中国水稻研究所 植物Cas9变体蛋白VQR及其编码基因与应用
SG11201810179RA (en) 2016-04-19 2018-12-28 Broad Inst Inc Novel crispr enzymes and systems
CN109312386B (zh) * 2016-06-15 2022-10-25 株式会社图尔金 使用中靶靶标和脱靶靶标的多重靶标系统筛选靶特异性核酸酶的方法及其用途
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
WO2018052247A1 (ko) 2016-09-13 2018-03-22 주식회사 툴젠 시토신 디아미나제에 의한 dna에서의 염기 교정 확인 방법
CA3039409A1 (en) 2016-10-07 2018-04-12 Integrated Dna Technologies, Inc. S. pyogenes cas9 mutant genes and polypeptides encoded by same
US11242542B2 (en) 2016-10-07 2022-02-08 Integrated Dna Technologies, Inc. S. pyogenes Cas9 mutant genes and polypeptides encoded by same
SG10201913505WA (en) 2016-10-17 2020-02-27 Univ Nanyang Tech Truncated crispr-cas proteins for dna targeting
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
AU2018273986A1 (en) 2017-05-25 2019-12-12 The General Hospital Corporation Bipartite base editor (BBE) architectures and type-II-C-Cas9 zinc finger editing
CN110914423B (zh) * 2017-05-31 2024-02-06 国立大学法人东京大学 经修饰的Cas9蛋白及其用途
US20200140835A1 (en) 2017-06-06 2020-05-07 The General Hospital Corporation Engineered CRISPR-Cas9 Nucleases
BR112020000310A2 (pt) 2017-07-07 2020-07-14 Toolgen Incorporated variantes de crispr alvo específicas
CA3073448A1 (en) 2017-08-23 2019-02-28 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
WO2019075197A1 (en) 2017-10-11 2019-04-18 The General Hospital Corporation METHODS OF DETECTION OF INDIVIDUAL SITE-SPECIFIC PARASITE GENOMIC DEAMINATION BY BASE EDITING TECHNOLOGIES
EP3707252A1 (en) 2017-11-10 2020-09-16 Novozymes A/S Temperature-sensitive cas9 protein
EP3781585A4 (en) 2018-04-17 2022-01-26 The General Hospital Corporation SENSITIVE IN VITRO TESTS FOR SUBSTRATE PREFERENCES AND SITE FOR NUCLEIC ACID BINDERS, MODIFIERS AND CLEAVAGE AGENTS
KR20250133482A (ko) 2018-05-11 2025-09-05 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일 뉴클레오티드 다형성을 편집하는 방법
US20230021641A1 (en) 2018-08-23 2023-01-26 The Broad Institute, Inc. Cas9 variants having non-canonical pam specificities and uses thereof
US20220411777A1 (en) 2019-08-30 2022-12-29 The General Hospital Corporation C-to-G Transversion DNA Base Editors
WO2021151073A2 (en) 2020-01-24 2021-07-29 The General Hospital Corporation Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants
WO2021151085A2 (en) 2020-01-24 2021-07-29 The General Hospital Corporation Crispr-cas enzymes with enhanced on-target activity

Similar Documents

Publication Publication Date Title
AU2023278074B2 (en) Engineered CRISPR-Cas9 nucleases with altered PAM specificity
ES3055163T3 (en) Class ii, type ii crispr systems
Liu et al. Expanding the CRISPR toolbox in zebrafish for studying development and disease
JP2023011629A (ja) 核酸塩基エディターのaav送達
JP2024138268A (ja) プログラム可能な塩基エディターシステムを用いて単一ヌクレオチド多型を編集する方法
Lone et al. CRISPR/Cas9 system: a bacterial tailor for genomic engineering
JP2020510439A5 (enExample)
Shirodkar et al. Epigenetics in cardiovascular disease
JP2020164529A (ja) 遺伝子編集用のcas多様体
JP2016512691A5 (enExample)
AU2014281026A1 (en) Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
AU2016316845A1 (en) Engineered CRISPR-Cas9 nucleases
Minarovits et al. Epigenetic regulation
JP2023540493A (ja) Rna誘導型rnaターゲティングcrisprエフェクターのための系、方法及び組成物
WO2020173150A1 (zh) 单碱基编辑导致非靶向单核苷酸变异及避免该变异的高特异性无脱靶单碱基基因编辑工具
Yoo et al. Dissecting tissue-specific super-enhancers by integrating genome-wide analyses and CRISPR/Cas9 genome editing
WO2024259295A2 (en) Reprogrammable fanzor polynucleotides and uses thereof
Jurkowska et al. Silencing of gene expression by targeted DNA methylation: concepts and approaches
Rasmussen The epigenetics of early development: inferences from stem cells
Zimmerman et al. Enhancement of transgene expression by nuclear transcription factor Y and CCCTC‐binding factor
Ramos-Hernández et al. Donor insertion into CX3CR1 allows epigenetic modulation of a constitutive promoter on hematopoietic stem cells and its activation upon myeloid differentiation
Zimmerman et al. Enhancement of Transgene Expression by NF-Y and CTCF
Rohm CRISPR/dCas9-Based Tools for Epigenome Editing
Sinha Effects of the H3. 3 K36M Oncohistone on the Dynamics of Gene Silencing and Epigenetic Memory
Enríquez Epigenome Editing